Venous thromboembolism and women's health

  title={Venous thromboembolism and women's health},
  author={Victoria Speed and Lara N. Roberts and Jignesh P. Patel and Roopen Arya},
  journal={British Journal of Haematology},
The prevention and treatment of venous thromboembolism (VTE) poses distinct gender‐specific challenges. Women of childbearing age are at an increased risk of VTE secondary to the transient risk factors of combined hormonal contraception (CHC) and pregnancy. Cancers specific to women are associated with a significant burden of VTE; whilst the incidence of VTE in localised breast cancer is 5 per 1000 person‐years, more cases are seen due to the prevalence of breast cancer. Treatment of VTE in… 

Obesity and venous thromboembolism

Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery

Chronic hypertension, high BMI, cancer type, and evidence of metastasis turned out to be the most significant risk factors for VTE in women who underwent breast surgery, and VTE occurrence significantly impacted survival in invasive breast cancer patients.

Special Considerations for Women of Reproductive Age on Anticoagulation

This practical guide for clinicians is designed to inform discussions of risks and benefits of anticoagulation therapy for women of reproductive age.

Venous thromboembolism in pregnancy

  • P. Wessels
  • Medicine
    South African Medical Journal
  • 2019
Pregnancy-related venous thromboembolic events are important preventable causes of morbidity and mortality in South Africa and must be kept in mind, as well as physiological changes leading to altered drug pharmacokinetics.

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.

Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquiredThrombophilia.


Direct oral anticoagulants used in fixed doses without laboratory monitoring are the agents of choice for the treatment of acute venous thromboembolism in the majority of patients and vitamin K antagonists or low-molecular weight heparins are still an alternative.

Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives

A narrative review of the key data published to date with compounds targeting factor XI to prevent thrombosis as well as the main ongoing clinical studies is proposed, opening up prospects for improving the care of patients requiring thromBosis prevention.

Hormones and Thrombosis: Risk Across the Reproductive Years and Beyond.

  • N. MachinM. Ragni
  • Medicine
    Translational research : the journal of laboratory and clinical medicine
  • 2020

Decision-Making in the Management of Venous Thromboembolism.

Inherited thrombophilic risk factors in Serbian breast cancer patients

The study noted the lack of association between common prothrombotic gene variants and increased prothROMbotic risk in Serbian breast cancer patients and pointed out possible role of MTHFR 677TT genotype in etiology of breast cancer, but further studies on larger cohort of patients are needed.



The prevention of pregnancy‐related venous thromboembolism

The importance of VTE in pregnancy and the puerperium, the part played by different risk factors and the role of thromboprophylaxis in this group of patients are described.

How I treat pregnancy-related venous thromboembolism.

Low-molecular-weight heparin in therapeutic doses is the treatment of choice during pregnancy, and anticoagulation (LMWH or vitamin K antagonists postpartum) should be continued until 6 weeks after delivery with a minimum total duration of 3 months.

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Hormonal therapy was not associated with an increased risk of recurrent VTE in women receiving therapeutic anticoagulation and the observed increasedrisk of abnormal uterine bleeding with rivaroxaban needs further exploration.

Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.

The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE, however, this risk is not significantly lower than in women whose VTE was not related to oestrogens use.

How I manage venous thromboembolism in pregnancy

  • R. Arya
  • Medicine
    British journal of haematology
  • 2011
Compression ultrasound is the test of choice for deep vein thrombosis and perfusion scan and computerized tomography pulmonary angiography are the imaging options for diagnosis of pulmonary embolism.

Venous Thromboembolism in Cancer Patients Undergoing Major Surgery

Recommendations can be made for the prevention of VTE in patients undergoing abdominal or pelvic surgery for cancer: risk-stratify all patients according to defined evidence-based guidelines, and consider extended-duration prophylaxis in those patients with major abdominal/pelvic operations and impaired mobility.

Venous thromboembolism: disease burden, outcomes and risk factors

  • J. Heit
  • Medicine
    Journal of thrombosis and haemostasis : JTH
  • 2005
VTE is a common, lethal disease that recurs frequently and causes serious long‐term complications, and to improve survival and prevent complications, VTE occurrence must be reduced.

Effect of Tamoxifen on Venous Thromboembolic Events in a Breast Cancer Prevention Trial

Women with conventional risk factors for atherosclerosis have a higher risk of VTE during tamoxifen therapy, and this information should be incorporated into counseling women on its risk-benefit ratio, particularly in the prevention setting.